



OUR ANNUAL REPORT

2017/18

thebraintumourcharity.org

Annual Report and Accounts

2017-2018

Contents

	Page
1. Report of the trustees	2
2. Statement of the trustees' responsibilities	20
3. Independent auditor's report	22
4. Statement of financial activities	24
5. Balance sheet	25
6. Cash flow statement	26
7. Notes to the financial statements	27

Report of the trustees for the year ended 31 March 2018

The trustees, who are also directors of The Charity for the purpose of the Companies Act, present their annual report together with the consolidated financial statements for The Charity and its subsidiary (together, 'the Group') for the year ended 31 March 2018, which are prepared to meet the requirements for a directors' report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice ('SORP') applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP)."

Chair and CEO's report



Last year, The Brain Tumour Charity passed the halfway point in its five-year strategy, *Defeating Brain Tumours*, and it's encouraging to reflect on how far we've come.

A real highlight of 2017/2018 was the news that The Charity had exceeded its strategic target of £20 million committed to research between 2015 and 2020, achieved by committing £9.1 million in research funding over the last year alone. In a world where too many charities put too much emphasis on raising money rather than spending it effectively, I'm delighted to see such dramatic evidence of the impact this charity can and does make. Our *Research Impact*

Report 2018 demonstrates how our investment is making an impact on both quality of life and survival rates.

It was also pleasing to see The Charity's HeadSmart campaign appear in their BBC Lifeline Appeal and go on to win a National Lottery Award in the Health category. HeadSmart, which helps clinicians to recognise the early symptoms of a brain tumour, has helped reduce average childhood brain tumour diagnosis times from 13 to 6.5 weeks. We are working to achieve a similar improvement in teenage and adult diagnosis times.

I have chaired The Charity for a little over three years, but will very shortly step down. I'm very pleased indeed that Jack Morris CBE will succeed me. We are lucky to have him. My contribution to The Charity has been extremely modest, but it has, nevertheless, been hugely rewarding. I've enjoyed working with, and am extremely grateful to Sarah Lindsell, The Charity's incredibly hardworking, caring and very effective Chief Executive. But the greatest privilege of the last three years has been to work with, and get to know, a remarkable group of trustees, particularly those who have experienced devastating loss and whose response has been to seek to prevent others experiencing similar tragedies. They are remarkable people and it's been humbling to observe their passion for defeating this terrible disease.

Finally, as The Charity continues to reach for its goals, I hope to see it drive collaboration and consolidation in the brain tumour charity sector. Now more than ever, it's imperative to strengthen the community by partnering with organisations who share a common purpose and values – only by working together will we make change happen.

Sir Martin Narey

Chair of Trustees, The Brain Tumour Charity



For The Brain Tumour Charity and the brain tumour community as a whole, 2017/2018 was about commitment to actions, not words. Baroness Tessa Jowell's decision to share news of her brain tumour diagnosis in September last year was a landmark moment for those affected by this disease, and her actions in the months that followed created an extraordinary momentum for change. Baroness Jowell spoke bravely and powerfully on the BBC and in the House of Lords about the urgent need for better treatments. Like us, she believed in the importance of more adaptive (flexible) clinical trials and of enabling patients around the world to share data to improve understanding of brain tumours and

drive the development of new treatments.

We were proud to play a key role in supporting her courageous and typically altruistic campaign, which has already helped us accelerate change. We recently announced a call for a new adaptive clinical trial to improve treatments for gliomas, the most common type of brain tumour. And we've made leaps and bounds in designing BRIAN, our global brain tumour databank, which will allow patients and researchers to gain insights into different tumour types and help us reach a cure quicker – Baroness Jowell demonstrated her commitment to actions when she signed up to BRIAN earlier this year.

But we know there is still much more to do. As we continue to work towards our vision of a world where brain tumours are defeated, we will hold ourselves accountable for Baroness Jowell's legacy and do everything we can to fulfil her pledge to help all those affected by a brain tumour to live longer and better lives.

Sarah Lindsell
CEO, The Brain Tumour Charity

Our vision

Our vision is for a world where brain tumours are defeated.

Our goals

1. Double survival by 2025
2. Halve the harm that brain tumours have on quality of life by 2020

Our values

Our values underpin our culture, the way we do things and what we believe in. We are **pioneering, passionate, collaborative** and **smart**.

A Cure Can't Wait

Going further for a cure

We think a cure for brain tumours simply can't wait. That's why we invest in pioneering research around the globe to help drive us towards our vision: a world where brain tumours are defeated. Over the last year we committed **£9.1 million** in research funding, including two Quest for Cures awards, and we're incredibly proud to report that just over halfway through our five-year strategy, *Defeating Brain Tumours*, we've already exceeded our target to commit an additional £20 million into research by 2020.

But we know that there is so much more to do. So we're already planning to invest an additional £12.5 million through our research strategy before 2020, to help us pick up the pace and make a difference to the lives of everyone diagnosed with a brain tumour.

We aim to spend 80p of every £1 spent on our charitable objectives

Sharing our progress



We recently published our **Research Impact Report 2018**, highlighting the progress we're making in the fight against brain tumours and the clinical benefits arising from the research we fund.

Among the many outstanding researchers featured in the report is Professor Susan Short, whose work has proved that a naturally-occurring virus ('reovirus') can cross the blood-brain barrier and attack tumour cells in the brain. The report also details the work of Professor Steve Clifford, whose research into medulloblastoma – the most common high grade tumour in children – is being used to improve survival and quality of survival through the development of tailored and targeted treatments.

Read the full report: thebraintumourcharity.org/impactreport

Pushing to the limits

In February, our inspiring trustee Rob Ritchie, whose son Toby has a low grade brain tumour, led **Everest in the Alps: The Second Ascent** to raise funds for The Everest Centre for Research into Paediatric Low Grade Brain Tumours. Rob was joined on the epic expedition by Phil Spencer, presenter of Channel 4's *Location, Location, Location* and *Love It or List It*, along with teams including Smith & Williamson, Barclays, JP Morgan, Goldman Sachs, BMS and Toby's Team. The skiers pushed themselves to the limits, ascending slopes equivalent to the height of Everest over four days in the Alps.

"Something that really resonates with me is talking about Toby's Everest and the challenges he faces. Everest in the Alps will make a difference for The Everest Centre and for vital research that just wasn't there before."

Phil Spencer

We're thrilled to share that Everest in the Alps: The Second Ascent raised £699,000 in 2017/2018, and, as of writing this report, had reached £1 million!



Innovative partnerships

We're committed to fighting brain tumours on all fronts, but we know that we can only accelerate progress by working with other like-minded organisations. That's why in January we partnered with Scotland-based charity Worldwide Cancer Research, committing an equal share of nearly £340,000 to fund researchers studying gliomas in Ireland and Australia. And in May, we partnered with Marie Curie to make a call for their fund for palliative and end of life care research, including areas that have until now received little attention.

Every Patient is a Research Patient

Progressing our patient-led databank

In our last Annual Report, we introduced our new global brain tumour databank. That databank now has a name – **BRIAN** (the **B**rain tumou**R** **I**nformation and **A**nalysis **N**etwork) – and we're delighted to report that, as of 31 March 2018, we had 250 completed consent forms and 40 expressions of interest from people affected by a brain tumour wanting to share their data. BRIAN will securely and anonymously store data about people's treatments, tumour types, experiences, side-effects and more, allowing patients and researchers to gain insights into different types of brain tumour and reach a cure quicker.

"When I was diagnosed with a brain tumour, I had to learn a lot about the disease in a short space of time. I wanted to know about other people – what treatment were they having? How were they feeling? But there was nowhere I could go to find this out. BRIAN will let people like me share their experiences with each other, and all this information will allow researchers to quickly identify which treatment is best and what support matters most."

Jess

"It is my hope that through my cancer journey and sharing of my data, we will be able to develop better treatments for cancer and speed up the discovery of new ones."

Baroness Tessa Jowell, who donated her data to BRIAN before her death in May 2018

Find out more: thebraintumourcharity.org/BRIAN

Involving patients in pioneering research

In February, we began accepting funding applications for **The Tessa Jowell Adaptive Clinical Trial** – an opportunity created to establish an adaptive clinical trial for glioma patients in the UK. The flexible design of the trial will allow more patients to be part of a clinical trial and access the newest treatments – something that Baroness Jowell felt strongly about (see page 7).

A number of other trials we're funding are or will be recruiting patients shortly, including **BIOMEDE**, the UK's first adaptive trial for children with a brain tumour. BIOMEDE will test improved treatments for children diagnosed with DIPG – one of the most deadly and aggressive childhood brain cancers. And we're also funding **PNET5** (see below), a trial studying improved treatments for children diagnosed with medulloblastoma.

Collaborating for a cure

Back in 2015, we founded our **Research Involvement Network (RIN)** to foster closer cooperation between the brain tumour patient and research communities, providing a way for those affected to use their personal experiences of this devastating disease to shape and inform research. We're proud to say that over the last year, the RIN has helped boost the number of patients contributing to research. The network gained 59 members in 2017/2018, bringing it to a total of 138 members across the UK.

RIN members were involved in 46 research projects in 2017/18.

Early and Accurate Diagnosis

Spreading the word with HeadSmart



In July, our BBC Lifeline Appeal aired, featuring our high profile supporter Tom Daley. The appeal focused on the pressing need for adult early diagnosis, but also showcased the continuing success of our award-winning **HeadSmart** campaign, which has helped to drive down average childhood brain tumour diagnosis times from 13 to 6.5 weeks. Following the appeal, we were thrilled by the announcement in September that HeadSmart had won a National Lottery Award in the Health category, having come out top in a public vote with over 1,300 entrants.

“Early diagnosis is key. If I hadn't taken him to the eye doctor we could have lost him. Often the tumour isn't spotted and the person just dies because there isn't time to save them. This is why HeadSmart is so important, for all parents. It can save lives.”

Philippa Forrester, whose son, Fred, was diagnosed with a brain tumour

But we know there's still more to do, so with the help of research led by Dr Paul Brennan (The University of Edinburgh) and Dr Fiona Walter (University of Cambridge), we're working towards identifying delays in adult brain tumour diagnosis times and raising awareness of the signs and symptoms of brain tumours in adults to enable earlier diagnosis.

Improving accuracy with PNET-5

We're excited to be investing over £680,000 in the **PNET5 clinical trial**, which aims to improve treatments for children diagnosed with medulloblastoma – the most common childhood brain tumour. Previous research funded by us identified seven sub-types of medulloblastoma, some of which can be classified as 'standard' or 'lower' risk. So to establish whether a child has a lower-risk medulloblastoma and aid recruitment to this vital

trial, we're also paying for all children diagnosed with a medulloblastoma in the UK to receive biomarker testing. This is the first time biomarker testing will be routine for those diagnosed with a brain tumour. With a more accurate diagnosis, all families affected by medulloblastoma will have a better understanding of the tumour, allowing them to make more informed decisions about treatments and quality of life.


Equal Access to the Best Treatment and Care

Actions not words

Baroness Tessa Jowell's decision to share her brain tumour diagnosis in September was a watershed moment for thousands of people affected by this devastating disease. In January, Baroness Jowell, who sadly passed away just before this report was written, spoke publicly about her brain tumour diagnosis on the BBC and in the House of Lords, and asked the Government to support her call to accelerate new treatments and improve patient care.

Baroness Jowell was committed to actions, not simply words, and her lobbying has already helped us drive progress by putting out a call for the UK's first adaptive clinical trial for glioma patients. We're also leading the way in developing a global brain tumour databank (see page 5), which Baroness Jowell highlighted the pressing need for. And we're proud that Baroness Jowell backed our campaign for 5-ALA (the 'pink drink', which makes brain tumour cells more easily visible to surgeons) to be rolled out to everyone who would benefit from it, something the Government has now pledged to enact across England.

Improving access to treatment and care



Back in 2016, we launched our **Patient Guide**, designed to inform people living with a brain tumour about the treatment and care they should expect and help them feel more confident in conversations with their medical team. At launch, we established a benchmark of current access to treatment and care via a survey on our website, and in 2017/2018 we conducted a second survey, which we were proud to see showed real improvements on the previous year. 16% of patients were now receiving all key elements of good practice outlined in the Guide, up from 8% in 2016. Patient access to 5-ALA (the 'pink drink') rose from 10% in 2016 to 45% last year. And we also saw a jump in the number of patients with a named key-worker, which improves patient experience – up from 38% in 2016 to 68% in 2017/2018.

Supporting patients all the way

Last year, in a landmark development in our drive to improve quality of life care for all those affected by a brain tumour, the neuro-oncology team at King's College Hospital welcomed our very first **Clinical Nurse Specialist (CNS)**. Charlotte Robinson now occupies the first funded low grade glioma CNS post in the UK. She hopes to develop a service that will establish a holistic support network to cater for all of a patient's needs.

"I want to do all I can to be there for patients with low grade brain tumours – whether that is with advice on symptom management or emotional support and someone to talk to. I'm really excited about what potential this role has for patients and hope to make their experience as straightforward as possible."

Charlotte

Only 53% of people with a low grade brain tumour said they had access to a single point of contact, compared to 76% with a high grade tumour.

Helping professionals get up to speed



In May, we held our second **Nurse and Allied Health Professional Study Day**, featuring talks on topics including clinical trials, mental health and driving. The event was CPD-accredited and attended by 160 delegates. Presenters included Professor Garth Cruickshank, Consultant Neurosurgeon at Queen Elizabeth Hospital, Birmingham and Dr Ruman Rahman, Assistant Professor of Molecular Neuro-Oncology, The University of Nottingham. By providing this opportunity for professionals to share knowledge and best practice, we hope to drive forward progress in improving life today for brain tumour patients, and accelerate equal access to the best treatment and care.

See the presentations here: thebraintumourcharity.org/learning-resources

80% of attendees said that attending a NAHP Study Day helped to improve their practice

Improving Life Today

The Price You Pay

Our *Life with a Brain Tumour* series of reports expose the physical, mental and emotional impact of a brain tumour. But what about the financial impact? Last year we did a survey to understand more about the effects of a brain tumour diagnosis on finances and patients' experiences navigating the UK benefits system. This led to the publication of our latest report, ***The Price You Pay: the Financial Impact of a Brain Tumour***, which highlights how having a brain tumour can seriously impact personal finances and the ability to work. The report details our recommendations to improve the process, and will be used to push for change in this area to help improve life today for everyone affected.

Read the report: thebraintumourcharity.org/price-you-pay

Supporting patients at work

The information gathered in our 2015 report *Losing Myself: The Reality of Life with a Brain Tumour* found that, of those asked:

- 3 in 4 people had their or their partner's working life affected
- 28% had to give up work entirely
- 1 in 2 experienced financial difficulties.

In October last year, we launched a new range of **Employment Resources** as a direct response to the needs and issues of our community. They were developed in response to a nationwide gap in information, and will help improve quality of life for those affected. They'll help people decide whether to talk to their employer about their diagnosis, what their employment rights are, and, if they do choose to share their diagnosis, provide tools to help them and their employer identify how best they can be supported at work.

"These packs are a great resource following a brain tumour diagnosis so that you know your rights in the workplace and what you're entitled to, and as a starting place for returning to a role once you're fit and ready."

Michaelagh, whose husband Harry is living with a brain tumour

United in our Battle to Defeat Brain Tumours

Baking a difference



In March, we kicked off Brain Tumour Awareness Month by donning bandanas and getting messy in the kitchen for our first ever **Big Bandana Bake**. Shrugging off the snowstorms, hundreds of bakers across the country united to raise awareness and vital funds to help defeat brain tumours. It was our biggest and best ever Brain Tumour Awareness Month. There were over 445 Big Bandana Bakes, and we're delighted to share that our bakers raised over £170,000! We want to say a huge thank you – this can help us fund over two years of a much-needed research project.

Making strides towards a cure

We're incredibly proud of everyone who came together to unite, share and celebrate at last year's **The Twilight Walk** – it was our most popular series of walks yet, with over 3,200 supporters joining forces to help stamp out brain tumours. We held three 10k walks in Chester, Warwick and Windsor, and for the first time our community organised a number of Own Walks in locations with special meaning to them. The spirited and moving atmosphere at each walk made this year's The Twilight Walk an incredibly special occasion – thank you to everyone who took part and volunteered: every step taken will bring us closer to a cure.



"We all said afterwards how lovely it was. It really felt like an event that everyone could be part of. There were older people, young kids – it was an event that a lot of people could take part in."

William, who walked in memory of his friend, Rachel

Our inspiring walkers raised £300,000, which will help us take vital steps towards defeating brain tumours.

Taking on brain tumours together

Our dedicated and courageous **Supporter Groups** continued to go above and beyond over the last year to make a real difference to the lives of people affected by a brain tumour. Supporter Groups are groups of people committed to ongoing fundraising for us in their loved one's name. Each Group can choose to allocate their funds to a specific area once £10,000 has been raised. In the last year, we welcomed 20 new Supporter Groups, bringing our total number to 297 and growing.

"I would hate for someone to go through what we have as a family, and have vowed to tirelessly raise money for The Brain Tumour Charity in memory of my beautiful mum and her courageous fight. With further research and understanding I hope one day it will prevent families in the future losing a loved one too soon to this horrendous, debilitating disease."

Katy, The Jackie Sutherland Memorial Fund

Our fantastic Supporter Groups raised over £1.1m* in 2017/2018.

*This figure includes all money raised directly by Supporter Groups as well as that generated by individuals associated with Supporter Groups in events such as the Virgin Money London Marathon.

Connecting our community

In March, we brought together a panel of globally renowned experts for our hugely successful **Ask the Researcher: Panel Edition** event at Kings College London. This was an opportunity for the public to hear from and put their questions to the panel, which included members of our scientific advisory board (SAB). The audience of over 170 people included those personally affected by a brain tumour, students, medical professionals and researchers. We're so grateful to the researchers involved for sharing their time and expertise, and for engaging with our brain tumour community to share developments, progress and future research plans.

Thanks

Last year The Charity continued to fund the highest quality research, and support thousands of people affected by a brain tumour. This work is only possible due to our dedicated supporters and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us. To everyone involved, we cannot thank you enough.

Trusts

BBC Children in Need
Robert Luff Foundation Limited
St James's Place Foundation

Elliott Simmons Charitable Trust
The Sir James Reckitt Charity

Family-led Charity Partners

Billie Butterfly Fund
OSCAR's Paediatric Brain Tumour Charity
Stay Strong Stu

Corporates

200 Degrees
ASV Global
Audit Scotland
Aykroyd & Sons
Barclays
Bluecube Technology Solutions
BMS
Carbon Clear
CDN London
Diageo
Dunnhumby
Edinburgh Woollen Mill
Evolution Coaching
Floor & Wall Ltd
Gateley PLC
Goldman Sachs
HSBC
IBM
Ipreo
J P Morgan
J P Morgan Cazenove
Knight Security

London & Partners
Macfarlanes LLP
Marriott London County Hall
Michelmores LLP
Moneycorp
Palletforce
R P Martin
RBC Global Asset Management
Relec Electronics
Resolute
SEC Recruitment
Seymour PR
Smith & Williamson
St Andrews Charity Fashion Show
Sulla Investments
The Collective
The Light Fund
Underbelly
Voip Unlimited
Waitrose
Wilton and Bain

Co-funding Partners

Action Medical Research
Cancer Research UK
Children with Cancer UK

Great Ormond Street Hospital Children's Charity
Medical Research Council
Worldwide Cancer Research

High profile supporters

Alastair Stewart OBE	Lorraine Kelly OBE
Alexander Stewart MSP	Marc Silk
Baroness Tessa Jowell	Martino Sclavi
Caroline Lucas MP	Matt Allwright
Chris White former MP	Mayor Christine Cross
Christopher Bailey	Mayor Jacquie Vosper
Councillor Margaret Rose	Mayor Vanessa Vasey
Dillon St.Paul	Mel Giedroyc
Dr Anthony Michalski	The Neales
Dr Chris Jones	Olivia Colman
Dr Colin Watts	Owain Arthur
Dr Paul Brennan	Philippa Forrester
Dr Steve Pollard	Professor Barry Pizer
Earl Spencer	Professor Denise Sheer
Ella and Matt Mills (Deliciously Ella)	Professor Keyoumars Ashkan
Emma McClarkin MEP	Professor Richard Gilbertson
Guy Opperman MP	Professor Susan Short
Hal Cruttenden	Russell Watson
Holly Matthews	Sorin Bucur
Jason Durr	Steve Backshall
Jess Mills	Tcheky Karyo
John Maynard	Tim Burgess and The Charlatans
Jonny Wilkinson CBE	Tom Daley
Liam Conlon	
Lewis Moody MBE	

We'd also like to thank the actress and writer Dawn French, one of the charity's first patrons and friend of Angela and Neil Dickson. Dawn recently donated prizes for a charity auction event and arranged bucket collections at her recent acclaimed one person show.

Trustees and Governance

Trustees

Sir Martin Narey (Chair)	Nigel McGinnity (resigned 22 January 2018)
Neil Dickson MBE (Vice Chair)	Justine McIlroy
Graham Lindsay (Vice Chair)	Philippa Murray
Tim Burchell	Berendina Norton
Angela Deacon	Graham Norton
Angela Dickson MBE	Professor Alan Palmer
Andy Foote	Robert Posner
Simon Hay	Rob Ritchie
Jack Morris CBE (appointed 29 March 2018)	

President

Professor Sir Colin Blakemore

Chief Executive Officer

Sarah Lindsell

Company Secretary

Andrew Warren (appointed 6 December 2017)

Angela Deacon (resigned 6 December 2017)

Registered Charity Number (England and Wales): 1150054

Registered Charity Number (Scotland): SC045081

Registered Company Number: 08266522

Registered office

Hartshead House
61-65 Victoria Road
Farnborough
Hampshire
GU14 7PA

Auditors

Menzies LLP
Lynton House
7-12 Tavistock Square
London
WC1H 9LT

Bankers

Lloyds Bank Plc
147 High Street
Guildford
GU1 3AG

Legal Advisors

Bates Wells Braithwaite LLP
Scandinavian House
2-6 Canon Street
London
EC4M 6YH

Governance

Biomedical Scientific Advisory Board (Biomed SAB)

Name

Professor Richard Gilbertson MBBS, PhD (*Chair*)
Dr Mark Gilbert MD (*Vice Chair*)

Dr David Adams PhD
Dr Kenneth Aldape MD

Professor Robert Brown PhD

Dr Susan Chang MD
Dr Eyal Gottlieb PhD (resigned March 2018)

Dr Paul Northcott PhD
Professor Nicola Sibson PhD

Professor Martin van den Bent MD, PhD
Dr Ian Waddell PhD

Institution

The Cambridge Cancer Centre, UK
The Centre for Cancer Research at the National Cancer Institute, USA

The Wellcome Trust Sanger Institute, UK
The Centre for Cancer Research at the National Cancer Institute, USA

Imperial College London and The Institute of Cancer Research, UK

The University of California, San Francisco, USA
The Technion Institute of Technology, Israel

St. Jude Children's Research Hospital, USA
The CRUK/MRC Oxford Institute for Radiation Oncology, UK

Erasmus University, The Netherlands
Charles River Laboratories, UK

Quality of Life Scientific Advisory Board (QoL SAB)

Name

Dr Antony Michalski MB ChB, MRCP, PhD, FRCPCH (*Chair*)

Professor Martin Taphoorn MD, PhD (*Vice Chair*)

Professor Terri Armstrong PhD, ANP-BC, FAANP

Dr Paul Brennan MB, BChir MRCS (Ed), PhD

Dr Rachel Cox MB, ChB, MRCP MA MD

Professor Filomena Maggino PhD

Dr Diane Puccetti MD

Professor Maggie Watson PhD, Dip.C.Psych, AFBPS

Institution

Great Ormond Street Hospital

The VU University Medical Center, Amsterdam

The National Institute of Health, USA

The University of Edinburgh

University Hospitals Bristol

Sapienza University of Rome, Italy

The University of Wisconsin

The Royal Marsden Hospital and University College London

Lay Advisors

Deborah Crossan

Christina Brincat

Professor Celine Boehm

Louise Edwards

Rachel Rathbone

Objectives for 2018 – 2019

The Charity continues to grow and deliver successfully on its charitable objectives, building on its position as the largest dedicated funder of research into brain tumours in the UK to become the leader in this field globally.

We have referred to the Charity Commission's general guidance on public benefit when reviewing our objectives and in planning our future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

The goals for 2018/19 have been set, maintaining our commitment to our long-term strategic objectives and in line with our five year strategy:

1. Commit up to £5.3m to ground-breaking research through our grant calls of Expanding Theories, Quality of Life, Clinical Biomarkers and Quest for Cures, to drive progress in defeating brain tumours.
2. Commit up to £2.5m to the Tessa Jowell Adaptive Clinical Trial, to improve treatments for adults and children with gliomas, the most common form of brain tumour.
3. Launch the first phase of our pioneering patient-led databank, BRIAN, and engage significant patient interest and commitment to it, to enable patients and researchers to learn from each other and reach a cure quicker.
4. Launch a campaign for earlier diagnosis in adults, based on the findings from our research projects, to improve adult early diagnosis times and help to save lives.
5. Widen our digital reach to increase awareness of brain tumours and access to our services, particularly amongst the newly diagnosed, so that we can continue improving life today for everyone with a brain tumour.
6. Better understand and further diversify our income streams in order to raise more funds for vital research, awareness and support.

Structure, governance and management

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum and articles of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new trustee. The Board operates an equal opportunities recruitment policy and trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction papers covering the role and responsibilities of trustees are provided to the trustees and governance updates are provided as and when appropriate. The trustees who served during the year are listed above.

The trustees meet four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All trustees give of their time freely and no trustee remuneration was paid in the year. Details of trustee expenses are disclosed in Note 8 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the trustees on performance and operations.

The Charity benefits from five sub-committees which have been established to advise on key areas of activity, which are:

- Finance Sub-Committee
- Research Sub-Committee
- Information and Support Sub-Committee
- Remuneration Sub-Committee
- Databank Sub-Committee

The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the Quality of Life Scientific Advisory Board (QoL SAB) can be found on page 14, set out under 'Governance'.

Accreditations

The Charity is a longstanding member of the Association of Medical Research Charities (AMRC). The AMRC is an umbrella organisation of the leading medical and health research charities in the UK. The Charity aims to follow the highest standards of accountability in medical and health research funding, and membership of AMRC requires the use of independent peer review in the allocation of all grants and awards for research. The Charity has twice received a best practice award for its peer review process.

The Charity has again been awarded The Information Standard and is a member of The Helplines Partnership.

The Charity is a member of the Fundraising Regulator. It is represented on a number of influential bodies and cancer campaigning groups.

Grant-making Policy

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

More than 11,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research Sub-Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

Approach to fundraising

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK. Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We do not engage with any third party fundraisers. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All fundraisers are required to demonstrate an understanding of the Code and make a commitment to uphold its values when they join The Charity.

We received 7 complaints this year relating to Fundraising which were all either to do with the content or timing of the communication. Brain tumours are a very sensitive subject and it is not always possible to know where someone is in their journey.

Finance review

Following on from last year's impressive income growth of 17%, we are pleased to see that this year's result saw a further 10% increase on last year's result of £8,600,686 taking our income to £9,430,212. This is an admirable achievement in light of the growing climate of mistrust of charities following a number of high profile scandals. A major contributor to this achievement was the second Everest in the Alps Challenge.

All of our services are free of charge for anyone whose life has been affected by a brain tumour. This, coupled with our research and awareness work, is only possible thanks to our dedicated supporters, as we receive no government or statutory funding and rely 100% on voluntary funding.


Income

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This is a strong position in an uncertain climate and provides greater security over future research commitments.

The year saw growth in income of 10% over the prior year to £9,430,212. (2016/17 £8,600,686). We added new events to our portfolio, increased the participation in our flagship event The Twilight Walk uniting over 3,000 supporters, and developed new fundraising tools. In addition the Everest in The Alps Challenge raised over £699k which was an outstanding achievement. We also raised over \$90k through our USA partners, A Kids' Brain Tumor Cure Foundation, for the Everest Centre.

Given there has been little growth in the sector with the top 100 charities reporting only a marginal increase of 1% on the previous year. (Charity financials top 100 fundraisers spotlight report) we remain cautiously optimistic about the future.

We are inspired by our supporters who continue to work extremely hard in raising the necessary funds to ensure we increase our investment in vital research, provide support and information to everyone who needs it, and raise awareness of the signs and symptoms of brain tumours.




* This figure is the amount raised directly by Supporter Groups. It excludes money generated by individuals associated with Supporter Groups in events such as the London Marathon.

Expenditure

Total expenditure increased by £1,567,157 in the year to £9,555,696.

Expenditure on our charitable activities increased by £1,075,633 in the year to £7,404,594, underpinned by a further significant increase in patient support. Further information about our achievements in the year are set out elsewhere in this report on pages 4-10. The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. This year we managed to spend 77p. This was below target due to the March 2018 research grant awards being lower than expected. Had the full research grant budget been awarded the figure would have been 81p. We have budgeted that 83p of every pound of our expenditure in 2018/19 will be on our charitable activities.

The Charity has one subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Limited made a profit of £13,362 which will be donated to The Charity.



Reserves policy

The reserves policy of The Charity is to maintain unrestricted funds of at least six months operational costs to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments, which is on average £3,731,718. The level of free reserves at 31 March 2018 were £5,851,824 made up of total reserves less restricted funds, designated funds and net book value of fixed assets (2017 - £5,609,494). At 31 March 2018 we had unaccrued but committed research expenditure totalling £14,121,899 that was subject to satisfying ongoing monitoring requirements.

Our Supporter Groups typically express a preference over how the funds they raise should be spent, these preferences usually include our research or support activities. Income raised by these Supporter Groups is designated by the trustees for the activities identified by each group. In addition, the trustees approved funding of a Chair position at a UK university, funds to cover this position have been classed as designated.

From time to time The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Sub-Committee meets on a quarterly basis to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

Investment policy

The investment of funds is controlled by the trustees who have appointed The Charity's Finance Sub-Committee to implement the trustees' investment decisions. Albert E Sharp and Smith & Williamson have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. In reaching investment decisions, the trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end The Charity had a £15.4m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. In a volatile year for investments the portfolio generated income of £282,669 and a valuation gain of £142,210.

Employees

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing the charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

Risk factors

The trustees have considered the major risks to which The Charity is exposed and have reviewed those risks and established systems and procedures to manage them. The Finance Sub-Committee reviews governance and risk during each year and makes recommendations on best practice to the trustees. The principal risks and uncertainties facing The Charity and how we endeavour to mitigate these are:

- We fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts.
- We are not able to commission enough high quality research projects. We are developing our engagement with the brain tumour research community and working to build capacity in the sector and we are looking at alternative research models. In addition we have extended funding through building relationships globally.
- We become affected by damage to our reputation or negative sentiment in the charity sector. We manage reputation risk through staff training and effective HR and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.
- Our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.
- We are the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 standard for datacentres and ensure that we have leading edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology.

Public benefit statement

The Brain Tumour Charity provides public benefit as a charity by:

- Supporting research into the nature, causes, diagnosis and treatment and social consequences of brain tumours.
- Relieving the suffering of people with brain tumours and their families and carers.
- Raising awareness and advancing public education in all areas relating to brain tumours.

The trustees have considered the Charity Commission's general guidance on public benefit and have taken it into account when reviewing The Charity's aims and objectives and in planning its future activities. The trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

Going concern

The trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks, and consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

Statement of the trustees' responsibilities

The trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure, of the Group for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the trustees on 12 July 2018 and signed on their behalf by:

Sir Martin Narey
Chair of Trustees

Independent auditor's report

Opinion

We have audited the financial statements The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2018 set out on pages 24 to 41. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and of the parent charitable company's affairs as at 31 March 2018 and of the group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the group's or the parent charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by The Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report including the Group strategic report for which the financial statements are prepared is consistent with the financial statements.
- the trustees' report and the Group strategic report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report including the Group strategic report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and proper accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remunerations specified by law not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

Use of our report

This report is made solely to the parent charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the parent charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the parent charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

Malcolm Lucas FCA (Senior Statutory Auditor)

for and on behalf of

Menzies LLP
Chartered Accountants
Statutory Auditor

Lynton House
7-12 Tavistock Square
London
WC1H 9LT

Date:

Consolidated Statement of Financial Activities for the year ended 31 March 2018

	Notes	Unrestricted Funds £	Restricted Funds £	Total 2018 £	Total 2017 £
Income and Expenditure					
Income from:					
Donations and legacies	3	6,609,650	1,714,152	8,323,802	7,197,578
Charitable activities	4	4,511	197,978	202,489	234,231
Other trading		502,488	102,357	604,845	916,920
Investments		299,076	-	299,076	251,957
Total income		7,415,725	2,014,487	9,430,212	8,600,686
Expenditure on:					
Raising funds		2,001,757	149,345	2,151,102	1,659,578
Charitable activities					
Research		3,623,972	776,695	4,400,667	4,186,370
Patient Support		1,975,120	155,831	2,130,951	1,077,080
Campaigning and raising awareness		791,138	81,838	872,976	1,065,511
Total expenditure on charitable activities		6,390,230	1,014,364	7,404,594	6,328,961
Total expenditure	5	8,391,987	1,163,709	9,555,696	7,988,539
Net income before gains and losses on investment assets		(976,262)	850,778	(125,484)	612,147
Realised and unrealised gains on investment assets		142,210	-	142,210	1,219,913
Net income/(expenditure)		(834,052)	850,778	16,726	1,832,060
Transfers		(77,284)	77,284	-	-
Net movement in funds for the year		(911,336)	928,062	16,726	1,832,060
Reconciliation of Funds					
Balances at 1 April 2017		9,248,548	2,743,613	11,992,161	10,160,101
Balances at 31 March 2018		8,337,212	3,671,675	12,008,887	11,992,161

The Statement of Financial Activities includes all gains and losses recognised in the year.

All incoming resources and resources expended derive from continuing activities.

The notes on pages 27-41 form part of these financial statements.

Consolidated Balance Sheet at 31 March 2018

Company number: 08266522

	Notes	Consolidated		Company	
		2018	2017	2018	2017
		£	£	£	£
Fixed Assets					
Intangible assets	11	64,688	88,633	64,688	88,633
Tangible assets	12	69,417	68,193	69,417	68,193
Investment in subsidiary	13	-	-	100	100
Investments	14	15,379,995	10,213,141	15,379,995	10,213,141
Current Assets					
Stock		8,051	7,797	-	-
Debtors	15	1,099,164	1,044,048	1,092,191	1,036,548
Cash at bank		4,032,952	7,447,408	4,032,711	7,445,879
		<u>5,140,167</u>	<u>8,499,253</u>	<u>5,124,902</u>	<u>8,482,427</u>
Creditors:					
Amounts falling due within one year	16	(8,645,380)	(6,877,059)	(8,643,577)	(6,875,687)
Net Current (Liabilities)/Assets		<u>(3,505,213)</u>	<u>1,622,194</u>	<u>(3,518,675)</u>	<u>1,606,740</u>
Total assets less current liabilities		<u>12,008,887</u>	<u>11,992,161</u>	<u>11,995,525</u>	<u>11,976,807</u>
Funds					
	20				
General reserve		5,985,928	5,766,320	5,972,566	5,750,966
Designated funds		2,351,284	3,482,228	2,351,284	3,482,228
Unrestricted funds		<u>8,337,212</u>	<u>9,248,548</u>	<u>8,323,850</u>	<u>9,233,194</u>
Restricted funds		3,671,675	2,743,613	3,671,675	2,743,613
		<u>12,008,887</u>	<u>11,992,161</u>	<u>11,995,525</u>	<u>11,976,807</u>

The financial statements were approved by the trustees on 12 July 2018 and signed on their behalf by:

.....
Sir Martin Narey
Chair of Trustees

.....
Neil Dickson MBE
Vice-Chair of Trustees

The notes on pages 27-41 form part of these financial statements.

Consolidated Cash Flow for the year ended 31 March 2018

	Total 2018 £	Total 2017 £
<u>Reconciliation of net income to net cash flow from operating activities</u>		
Net income for the year	16,726	1,832,060
Adjustments for:		
Depreciation charges	57,728	45,157
Gains on investments	(138,119)	(1,219,913)
Dividends, interest and rents from investments	(299,076)	(251,957)
(Increase)/decrease in stocks	(254)	2,716
Increase in debtors	(55,116)	(604,158)
Increase in creditors	1,768,321	2,203,185
Net cash provided by operating activities	<u>1,350,210</u>	<u>2,007,090</u>

	Total 2018 £	Total 2017 £
<u>Statement of cash flows</u>		
Cash flows from operating activities		
Net cash provided by (used in) operating activities	1,350,210	2,007,090
Cash flows from investing activities:		
Dividends, interest and rents from investments	270,341	217,148
Purchase of computer software	0	(77,019)
Purchase of property, plant and equipment	(35,007)	(17,477)
Purchase of investments	(5,000,000)	-
Net cash provided by/(used in) investing activities	<u>(4,764,666)</u>	<u>122,652</u>
Change in cash and cash equivalents in the year	<u>(3,414,455)</u>	<u>2,129,742</u>
Cash and cash equivalents at 1 April 2017	7,447,408	5,317,666
Cash and cash equivalents at 31 March 2018	<u>4,032,953</u>	<u>7,447,408</u>

Notes to the Financial Statements

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2016) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 13. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 2.

2. Accounting Policies

(a) Basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net outgoing resources for The Charity in the year were £3,365 (2017: incoming £1,840,319).

The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared in accordance with the Statement of Recommended Practice "Accounting and Reporting by Charities" effective 1 January 2015, and in accordance with applicable accounting standards and the Companies Act 2006.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) Company status

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 13. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

(c) Income

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. As the result of a move to a new financial system these allocations are more refined this year and therefore differ from those in previous years.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

(e) **Stocks**

Stock is measured at the lower of cost and net realisable value.

(f) **Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) **Fixed assets**

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) **Estimated useful lives**

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) **Investments**

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) **Donated Assets and Services**

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) **Operating lease**

The Charity classifies the lease of Hartshead House as an operating lease. Rental charges are provided over the term of the lease (5 years).

(l) **Pensions**

The charitable company operates two defined contributions pension schemes. The schemes are funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independent of the charitable company's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) Going concern

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees. The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

3. Donations and legacies

	2018		2017			
	Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
	£	£	£	£	£	£
Ordinary activities:						
Regular giving	173,491	10,146	183,637	148,457	2,449	150,906
Donations, appeals and fundraising	4,879,431	1,580,807	6,460,238	4,673,890	863,468	5,537,358
Gift Aid	600,063	23,199	623,262	424,246	13,003	437,249
Legacies	956,665	100,000	1,056,665	1,072,065	-	1,072,065
	<u>6,609,650</u>	<u>1,714,152</u>	<u>8,323,802</u>	<u>6,318,658</u>	<u>878,920</u>	<u>7,197,578</u>

4. Income from charitable activities

Income from charitable activities includes a grant of £197,957 (2017: £229,733) from Children with Cancer UK to support our INSTINCT research programme at Newcastle University.

5. Analysis of resources expended

	Direct	Grants	Support	2018
	Costs		Costs	Total
	£	£	£	£
Raising funds	2,029,145	-	121,957	2,151,102
Charitable activities:				
Research	830,895	3,533,185	36,587	4,400,667
Patient Support	2,065,907	-	65,044	2,130,951
Campaigning and raising awareness	771,346	-	101,630	872,976
Total expenditure on charitable activities	<u>3,668,148</u>	<u>3,533,185</u>	<u>203,261</u>	<u>7,404,594</u>
Total expenditure	<u>5,697,293</u>	<u>3,533,185</u>	<u>325,218</u>	<u>9,555,696</u>

	Direct Costs £	Grants £	Support Costs £	2017 Total £
Raising funds	1,431,023	-	228,555	1,659,578
Charitable activities:				
Research	416,121	3,643,926	126,323	4,186,370
Patient Support	910,912	-	166,168	1,077,080
Campaigning and raising awareness	772,144	-	293,367	1,065,511
Total expenditure on charitable activities	<u>2,099,177</u>	<u>3,643,926</u>	<u>585,858</u>	<u>6,328,961</u>
Total expenditure	<u>3,530,200</u>	<u>3,643,926</u>	<u>814,413</u>	<u>7,988,539</u>

6. Research grant cost analysis

	2018 £	2017 £
Research programmes	2,273,963	2,028,551
Research projects	928,658	1,237,387
Clinical trials	133,415	219,609
Fellowships	163,479	146,361
Conferences	33,670	12,018
	<u>3,533,185</u>	<u>3,643,926</u>

A breakdown of research costs by individual award is provided in note 23.

7. Support costs by activity

	Finance and Human resources £	Central facilities £	Information technology £	Central management £	Governance £	Total £
Raising funds	50,436	17,083	21,686	2,112	30,640	121,957
Charitable activities:						
Research	15,131	5,125	6,506	633	9,192	36,587
Patient Support	26,899	9,111	11,566	1,126	16,341	65,044
Campaigning and raising awareness	42,030	14,236	18,072	1,760	25,533	101,630
2018 Total	<u>134,496</u>	<u>45,555</u>	<u>57,830</u>	<u>5,631</u>	<u>81,706</u>	<u>325,218</u>

	Finance and Human resources £	Central facilities £	Information technology £	Central management £	Governance £	Total £
Raising funds	79,760	66,949	62,376	5,115	14,355	228,555
Charitable activities:						
Research	31,876	26,756	24,929	2,044	40,718	126,323
Patient Support	58,472	49,080	45,728	3,750	9,138	166,168
Campaigning and raising awareness	106,356	89,272	83,176	6,821	7,742	293,367
2017 Total	<u>276,464</u>	<u>232,057</u>	<u>216,209</u>	<u>17,730</u>	<u>71,953</u>	<u>814,413</u>

8. Governance costs

	2018	2017
	£	£
Auditor's remuneration	15,900	13,390
Premises costs and insurances	7,800	5,587
Trustee meeting	5,287	4,176
Legal and professional fees	3,061	1,263
Staff	49,657	47,537
	<u>81,705</u>	<u>71,953</u>

Trustees received no remuneration (2017: £nil). Four trustees were reimbursed for expenses in the year totalling £1,175 (2017: five for £2,081). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2017: £nil).

9. Staff costs

	2018	2017
	£	£
Wages and salaries	3,041,360	2,295,342
Social security costs	284,685	220,086
Pension	138,643	97,412
	<u>3,464,688</u>	<u>2,612,840</u>

The average number of employees during the year was 100 (2017: 85).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2018	2017
£60,001 - £70,000	2	4
£70,001 - £80,000	1	2
£80,001 - £90,000	1	1
£90,001-£100,000	1	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £619,009 (2017 £585,924).

10. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

11. Intangible fixed assets

Group and Company

	Computer Software £
Cost	
At 1 April 2017	120,712
Additions	0
At 31 March 2018	<u>120,712</u>
Depreciation	
At 1 April 2017	32,079
Charge for period	23,945
At 31 March 2018	<u>56,024</u>
Net Book Value	
At 31 March 2018	<u>64,688</u>
At 31 March 2017	<u>88,633</u>

12. Tangible fixed assets

Group and Company

	Leasehold Improvements £	Computers and Office Equipment £	Total £
Cost			
At 1 April 2017	59,569	124,691	184,260
Additions	-	35,007	35,007
At 31 March 2018	<u>59,569</u>	<u>159,698</u>	<u>219,267</u>
Depreciation			
At 1 April 2017	29,894	86,173	116,067
Charge for period	11,303	22,480	33,783
At 31 March 2018	<u>41,197</u>	<u>108,653</u>	<u>149,850</u>
Net Book Value			
At 31 March 2018	<u>18,372</u>	<u>51,045</u>	<u>69,417</u>
At 31 March 2017	<u>29,675</u>	<u>38,518</u>	<u>68,193</u>

13. Investment in subsidiary undertaking

Cost

At 1 April 2017 and 31 March 2018	£ <u>100</u>
-----------------------------------	-----------------

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

At 31 March 2018 the aggregate of the share capital and reserves of TBTC Trading Ltd was £13,462 (2017: £100).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2018	2017
	£	£
Turnover	66,630	70,737
Cost of sales	(18,044)	(21,077)
Gross profit	<u>48,586</u>	<u>49,660</u>
Other operating expenses	(35,224)	(34,306)
Profit before donation	<u>13,362</u>	<u>15,354</u>
Donation	-	(15,354)
Retained profit	<u>13,362</u>	<u>-</u>

Cost of sales represent cost of stock sold in the year.

At the year end the aggregate assets of TBTC Trading Ltd were £13,462 (2017: £16,826), aggregate liabilities £13,362 (2017: £16,726) and shareholder's funds £100 (2017: £100).

14. Investments

Group and Company	£	
At 1 April 2017	10,213,141	
Additions at cost	5,000,000	
Disposals	-	
Net unrealised gain on revaluation	166,854	
At 31 March 2018	<u>15,379,995</u>	
Historical cost	<u>14,275,358</u>	
	2018	2017
	£	£
Investments at market value comprised:		
UK Equities	3,734,554	5,947,631
Overseas Equities	3,424,760	-
Absolute return funds	1,926,047	1,394,930
Multi asset funds	196,080	-
Alternative investments	57,446	-
Fixed income securities	5,998,035	2,870,580
Cash held within the investment portfolios	14,338	-
Accrued income	28,735	-
At 31 March 2017	<u>15,379,995</u>	<u>10,213,141</u>

During the year income from listed investments was £282,669 (2017: £230,116) and interest on deposits £16,407 (2017: £22,654).

15. Debtors

	Consolidated		Company	
	2018	2017	2018	2017
	£	£	£	£
Trade debtors	180,330	170,956	180,175	170,956
Accrued income and prepayments	231,348	230,006	224,419	222,506
Other debtors	687,489	643,086	687,489	643,086
Amounts owed by TBTC Trading Ltd	-	-	111	-
	<u>1,099,164</u>	<u>1,044,048</u>	<u>1,092,191</u>	<u>1,036,548</u>

16. Creditors

	Consolidated		Company	
	2018	2017	2018	2017
	£	£	£	£
Grants payable	7,896,270	6,252,583	7,896,270	6,252,583
Accruals and deferred income	402,028	402,074	398,956	400,074
Creditors	246,001	105,106	245,088	105,106
Amounts owed to TBTC Trading Ltd	-	-	-	2,158
Other creditors	18,649	51,400	18,649	51,400
Social Security and other taxes	82,432	65,896	84,614	64,366
	<u>8,645,380</u>	<u>6,877,059</u>	<u>8,643,577</u>	<u>6,875,687</u>

17. Research commitments

At 31 March 2018 The Charity had authorised commitments that were subject to outstanding conditions amounting to £14,121,819 (2017: £8,694,640), these are expected to fall due as follows:

	2018	2017
	£	£
Within one year	3,899,705	3,007,642
Between one and two years	3,772,889	2,572,036
Between two and three years	3,214,211	1,576,004
Between three and four years	2,092,502	1,538,958
Between four and five years	663,719	-
Five years and further	478,793	-
	<u>14,121,819</u>	<u>8,694,640</u>

18. Operating lease commitments

The total of future minimum property lease payments on operating leases are as follows:

	Consolidated		Company	
	2018	2017	2018	2017
	£	£	£	£
Within one year	102,000	102,000	72,000	72,000
Between one and five years	110,500	8,500	78,000	6,000
	<u>212,500</u>	<u>110,500</u>	<u>150,000</u>	<u>78,000</u>

Operating lease charges during 2018 were £102,000 for property (2017: £102,000).

19. Analysis of net assets between funds

	Unrestricted Funds £	Restricted Funds £	Total 2018 £
Intangible fixed assets	64,688	-	64,688
Tangible fixed assets	69,417	-	69,417
Investments	15,379,995	-	15,379,995
Other current assets	(508,070)	5,648,237	5,140,167
Current liabilities	(6,667,015)	(1,976,562)	(8,643,577)
	<u>8,337,212</u>	<u>3,671,675</u>	<u>12,008,887</u>

19 Analysis of net assets between funds continued

	Unrestricted Funds £	Restricted Funds £	Total 2017 £
Intangible fixed assets	88,633	-	88,633
Tangible fixed assets	68,193	-	68,193
Investments	10,213,141	-	10,213,141
Other current assets	4,301,681	4,197,572	8,499,253
Current liabilities	(5,423,100)	(1,453,959)	(6,877,059)
	<u>9,248,548</u>	<u>2,743,613</u>	<u>11,992,161</u>

20. Funds

Consolidated	At	Incoming Resources	Resources Expended	Fund Transfers	Investment Gains	At
	1 April 2017					31 March 2018
	£	£	£	£	£	£
Restricted funds:						
Research funds	334,621	685,466	(778,166)	-	-	241,921
Everest Fund	2,007,247	735,996	(66,759)	-	-	2,676,484
Awareness funds	119,390	25,486	(92,799)	300,091	-	352,168
Support funds	282,355	567,539	(225,985)	(222,807)	-	401,102
	<u>2,743,613</u>	<u>2,014,487</u>	<u>(1,163,709)</u>	<u>77,284</u>	<u>-</u>	<u>3,671,675</u>
Unrestricted funds:						
General reserve	5,766,320	6,637,313	(6,450,491)	(109,424)	142,210	5,985,928
Designated funds	3,482,228	778,412	(1,941,496)	32,140	-	2,351,284
	<u>9,248,548</u>	<u>7,415,725</u>	<u>(8,391,987)</u>	<u>(77,284)</u>	<u>142,210</u>	<u>8,337,212</u>
	<u>11,992,161</u>	<u>9,430,212</u>	<u>(9,555,696)</u>	<u>-</u>	<u>142,210</u>	<u>12,008,887</u>

Company	At	Incoming Resources	Resources Expended	Fund Transfers	Investment Gains	At
	1 April 2017					31 March 2018
	£	£	£	£	£	£
Restricted funds:						
Research funds	334,621	685,466	(778,166)	-	-	241,921
Everest Fund	2,007,247	735,996	(66,759)	-	-	2,676,484
Awareness funds	119,390	25,486	(92,799)	300,091	-	352,168
Support funds	282,355	567,539	(225,985)	(222,807)	-	401,102
	<u>2,743,613</u>	<u>2,014,487</u>	<u>(1,163,709)</u>	<u>77,284</u>	<u>-</u>	<u>3,671,675</u>
Unrestricted funds:						
General reserve	5,750,966	6,570,683	(6,397,223)	(94,070)	142,210	5,972,566
Designated funds	3,482,228	778,412	(1,941,496)	32,140	-	2,351,284
General fund	<u>9,233,194</u>	<u>7,349,095</u>	<u>(8,338,719)</u>	<u>(61,930)</u>	<u>142,210</u>	<u>8,323,850</u>
	<u>11,976,807</u>	<u>9,363,582</u>	<u>(9,502,428)</u>	<u>15,354</u>	<u>142,210</u>	<u>11,995,525</u>

Consolidated	At 1 April 2016 £	Incoming Resources £	Resources Expended £	Investment Gains £	At 31 March 2017 £
Restricted funds:					
Research funds	425,923	681,830	(773,132)	-	334,621
Everest Fund	3,049,544	113,449	(1,155,746)	-	2,007,247
Awareness and knowledge funds	310,542	51,440	(242,592)	-	119,390
Support funds	30,382	512,725	(260,752)	-	282,355
	<u>3,816,391</u>	<u>1,359,444</u>	<u>(2,432,222)</u>	<u>-</u>	<u>2,743,613</u>
Unrestricted funds:					
General reserve	3,135,958	6,564,388	(5,153,939)	1,219,913	5,766,320
Designated funds	3,207,752	676,854	(402,378)	-	3,482,228
	<u>6,343,710</u>	<u>7,241,242</u>	<u>(5,556,317)</u>	<u>1,219,913</u>	<u>9,248,548</u>
	<u>10,160,101</u>	<u>8,600,686</u>	<u>(7,988,539)</u>	<u>1,219,913</u>	<u>11,992,161</u>
Company	At 1 April 2016 £	Incoming Resources £	Resources Expended £	Investment Gains £	At 31 March 2017 £
Restricted funds:					
Research funds	425,923	681,830	(773,132)	-	334,621
Everest Fund	3,049,544	113,449	(1,155,746)	-	2,007,247
Awareness and knowledge funds	310,542	51,440	(242,592)	-	119,390
Support funds	30,382	512,725	(260,752)	-	282,355
	<u>3,816,391</u>	<u>1,359,444</u>	<u>(2,432,222)</u>	<u>-</u>	<u>2,743,613</u>
Unrestricted funds:					
General reserve	3,112,345	6,517,265	(5,098,557)	1,219,913	5,750,966
Designated funds	3,207,752	676,854	(402,378)	-	3,482,228
General fund	<u>6,320,097</u>	<u>7,194,119</u>	<u>(5,500,935)</u>	<u>1,219,913</u>	<u>9,233,194</u>
	<u>10,136,488</u>	<u>8,553,563</u>	<u>(7,933,157)</u>	<u>1,219,913</u>	<u>11,976,807</u>

Purpose of restricted funds

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 23.
Everest fund	During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated Funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

21. Related parties

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd. TBTC Trading Ltd acts as a sales agent on behalf The Charity. At 31 March 2018 TBTC Trading Ltd owed The Charity £111 (2017: The Charity owed TBTC Trading Ltd £2,158).

Trustees made donations to The Charity totalling £106,360 during the year (2017 £3,360) and paid contributions totalling £65,976 (2017 £7,730) during a number of our fundraising events.

22. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated the area of our activity is identified:

	£	Charitable activity:
BBC Children In Need	21,436	Sam's project
Billie Butterfly Fund	122,625	ICR – Jones – project grant
Children with Cancer UK	197,958	Newcastle - programme grant
Robert Luff Foundation Limited	50,000	Quest for cures grant (Pollard)
OSCAR's Paediatric Brain Tumour Charity	25,000	Quest for Cures Grant (Chesler)
St James's Place Foundation	31,275	Sam's project
The Sir James Reckitt Charity	10,000	Support Services
Elliott Simmons Charitable Trust	100,000	Teens and young adults service
Stay Strong Stu	16,426	

23. Research awards

	2018	2017
	£	£
Newcastle - Programme - Prof Clifford	385,203	-
UCL - Programme - Dr Pollard	-	(13,857)
Newcastle - Programme - Prof Clifford	-	466,484
UCL - Programme - Prof Salomoni	-	7,603
QMUL - SIGNAL Programme - Prof Sheer	200,000	200,000
Leeds - Programme - Prof Short	246,000	236,000
Edinburgh - Programme - Dr Pollard	285,856	-
German CRC - Programme - Dr Jones	-	1,132,321
Southampton - Clinical Trials - QOL - PNET5 - Prof Kennedy	68,692	-
VUMC Amsterdam - Programme - Quest - Dr Wurdinger	398,402	-
University Health Network - Programme - Quest - Dr Zadeh	193,000	-
St Jude's - Programme - MERIT - Dr Northcott	301,435	-
Colorado - Programme - Adamantinomous Craniopharyngioma - Dr Hankinson	195,375	-
Glasgow - Project - Prof Chalmers	(22,216)	62,348
UCL - Project - Dr Michod	-	43,131
Cambridge - Project - Dr Turner	-	4,534
Cambridge - Project - Prof Collins	-	(9,559)
Cambridge - Project - Dr Walter	-	28,546
Edinburgh - Project - Dr Brenan	-	124,808
Project - Paradigm Sample Collection	1,655	8,164
UCL - Project - Dr Clark	-	114,384
Southampton - Project - The PROMOTE Study - Prof Kennedy	101,476	107,361
Alder Hey - Project - Dr Mallucci	-	34,307
Imperial - Project - Prof Waldman	61,336	-
SGC Open Source - Project	200,000	-
Nottingham - Project - Dr Dixon	-	98,549
Queensland - Project - Dr Mazziari	-	99,925
Cambridge - Project - Prof Watts	-	100,000
Nottingham - Project - Dr Rahman	-	81,359
Montreal - Project - Dr Jahani-Asi	-	99,722
Kings - Project - Dr Al-Jamal	-	98,462
Durham - Project - Dr Gill	-	75,022
QMUL - Project - Dr Ribeiro	-	74,488
ICR - Billie Butterfly - Project - Prof Jones	77,810	-
Edinburgh - Project - QOL - Dr Rooney	104,278	-
Newcastle - Project - QOL - Prof Sharp	82,550	-
Trinity - Project - PRC2 Deregulation 1 - Prof Bracken	42,200	-
Monash - Project - Tumorigenesis - Prof Wong	30,000	-
Leeds - Project - Nanobiopsy - Dr Stead	97,150	-
Erasmus, Rotterdam - Project - CEST MRI - Dr Smits	54,200	-
Nottingham - Project - STAT3 - Dr Serres	47,779	-
Telethon Kids Institute - Project - Ion Channel Drugs - Prof Johns	50,440	-
Cambridge - Clinical Trial - Dr Baird	-	10,805
Birmingham - Clinical Trial - Dr Hargrave	23,276	23,220
Birmingham - Clinical Trial - Dr Picton	13,900	13,259
Birmingham - Clinical Trial Support - Dr Kearns	-	88,507
Glasgow - Clinical Trial - PARADIGM2 - Prof Chalmers	27,976	31,104
Leeds - Clinical Trial - Prof Short	-	25,009
Leeds - Clinical Trial - Dr Samson	-	19,541
Birmingham - Clinical Trials - PNET5 - Dr Kearns	43,732	-
AKT Inhibitor - Clinical Trial - Prof Chalmers	24,531	-
Research awards sub-total carried forward	<u>3,336,036</u>	<u>3,485,547</u>

23. Research awards (continued)

	2018 £	2017 £
Research awards sub-total brought forward	3,336,036	3,485,547
Nottingham - Fellowship - Dr Adhikaree	-	38,472
Bristol - Fellowship - Mr Singleton	-	37,734
QML - Fellowship - Dr Millner	103,479	70,155
St Jude's - Fellowship - Future Leaders - Dr Bihannic	60,000	-
Glasgow - Conferences - Prof Chalmers	-	2,658
NCRI - Meetings - Prof Watts	-	4,160
NHS Lothian - Meetings - Dr Grant	-	2,000
Glasgow - Meetings - Prof Chalmers	-	2,850
Conference - Medulloblastoma in the Mountains - Prof Clifford	18,117	-
Conference - Sanon Sinapse 2017 - Prof Chalmers	2,593	-
3rd CNS Anticancer Drug Discovery and Development Conference	5,000	-
International Oncolytic Virus Conference - Glioblastoma Symposium	5,000	-
Conference - NCRI Early Diagnosis Incubator Day	2,960	-
Other conferences	-	350
Total research awards	<u>3,533,185</u>	<u>3,643,926</u>